{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:55:17Z","timestamp":1788292517250,"version":"build-2803163510"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"WHO Country Office Pakistan, Expanded Programme on Immunization (EPI) Unit"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: The International Agency for Research on Cancer estimated around 3197 annual deaths along with 5008 newly diagnosed cases of cervical cancer in Pakistan. Worldwide, introduced in 164 WHO member states, the HPV vaccine provides over ninety percent (90%) protection from human papillomavirus (16 &amp; 18 types) infections. This article intended to document the vaccine (HPV) introduction in a low-middle-income country through the lens of EPI preparedness, vaccination coverage achieved, community acceptance, and implementation challenges during Phase I. Methodology: The research applied a qualitative and quantitative mix method to review the intricate procedure of new vaccine rollout within the national context. A qualitative participant observation approach assessed the planning, approval, and implementation phases of the HPV vaccine. Quantitative data statistics were evaluated for national &amp; regional vaccination coverages, rapid convenience assessment findings, and adverse events reports. Results: The overall reported administrative HPV campaign coverage was 75%, with the maximum regional coverage of 81% by the Punjab, followed by 66% of the Sindh, 43% by the Azad Jammu &amp; Kashmir, and 38% by the Islamabad. Rapid Convenience Assessment findings highlighted the main reasons for refusal (71%), with unavailable girls during the campaign (22%) for non-HPV vaccination. Community acceptance varied across the regions, with notable challenges in implementation being observed. Discussion &amp; Way Forward: Initial phase campaign coverage (70.6%) was greater than the worldwide reported first dose mean coverage (61.6%) for the same multi-age cohort, indicative of an encouraging start in resource limited setting. Documented coverage was below the high-performing countries but comparable to multiple low and middle-income countries. Federal Directorate of Immunization, in collaboration with provincial EPI stakeholders, should prioritize including the newly introduced HPV vaccine in the routine immunization schedule of the Phase I regions and should also implement the lessons learned in the subsequent rollout phases in 2026 in Khyber Pakhtunkhwa and 2027 in Balochistan &amp; Gilgit Baltistan. Expanding fixed EPI sites for HPV vaccination, promoting school-centered vaccination, rationalizing outreach in marginalized areas, sustaining the cold chain system, implementing a culturally acceptable communication plan, and resolving internet connectivity challenges are the key strategies to address implementation challenges.<\/jats:p>","DOI":"10.3390\/vaccines14060537","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:19:53Z","timestamp":1781691593000},"page":"537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pakistan\u2019s 2025 HPV Vaccine Phase I Rollout: Community Response, Implementation Challenges &amp; Way Forward"],"prefix":"10.3390","volume":"14","author":[{"given":"Wei","family":"Xia","sequence":"first","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9147-5911","authenticated-orcid":false,"given":"Soofia","family":"Yunus","sequence":"additional","affiliation":[{"name":"Federal Directorate of Immunization (FDI), Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atta Ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Nawaz","family":"Jiskani","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imran","family":"Qureshi","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawana","family":"Farooq","sequence":"additional","affiliation":[{"name":"Federal Directorate of Immunization (FDI), Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inam","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Federal Directorate of Immunization (FDI), Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-9802","authenticated-orcid":false,"given":"Sunday","family":"Audu","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Natiq Abbas","family":"Kazmi","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozina","family":"Khalid","sequence":"additional","affiliation":[{"name":"WHO Country Office, Prime Minister\u2019s National Health Complex, Park Road, Chak Shahzad, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref_1","unstructured":"WHO (2020). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem, World Health Organization."},{"key":"ref_2","first-page":"322","article-title":"Global burden of cervical cancer: Current estimates, temporal trend and future projections based on the GLOBOCAN 2022","volume":"5","author":"Wu","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_3","unstructured":"WHO (2024). Cervical Cancer, W.H. Organization."},{"key":"ref_4","unstructured":"Gebreal, A., Ashmawy, R.A., Ahmed, M., Khattab, M., Shata, K., Elmansoury, A., Estifanos, H., and Ghazy, R. (2025, January 20\u201323). Parental Acceptance of Human Papillomavirus Vaccination and its Determinants in the Eastern Mediterranean Region: A Systematic Review and Meta-Analysis. Proceedings of the Consortium of Universities for Global Health 2025, Atlanta, GA, USA."},{"key":"ref_5","first-page":"26","article-title":"Human papillomavirus and related diseases report","volume":"7","author":"Bruni","year":"2019","journal-title":"ICO\/IARC Inf. Cent. HPV Cancer HPV Inf. Cent."},{"key":"ref_6","first-page":"625","article-title":"National cancer registry of Pakistan: First comprehensive report of cancer statistics 2015\u20132019","volume":"33","author":"Ikram","year":"2023","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chughtai, N., Perveen, K., Gillani, S.R., Abbas, A., Chunara, R., Manji, A.A., Karani, S., Noorali, A.A., Zakaria, M., and Shamsi, U. (2023). National cervical cancer burden estimation through systematic review and analysis of publicly available data in Pakistan. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15531-z"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25151355251356646","DOI":"10.1177\/25151355251356646","article-title":"Cervical cancer trends, HPV vaccine utilization, and screening in low-and lower-middle-income countries: An updated review","volume":"13","author":"Hamid","year":"2025","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Loya, A., Serrano, B., Rasheed, F., Tous, S., Hassan, M., Clavero, O., Raza, M., De Sanjos\u00e9, S., Bosch, F.X., and Alemany, L. (2016). Human Papillomavirus genotype distribution in invasive cervical cancer in Pakistan. Cancers, 8.","DOI":"10.3390\/cancers8080072"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijid.2006.06.007","article-title":"Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma","volume":"11","author":"Khan","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","unstructured":"Fund, S. (2025, November 30). Sustainable Development Goals. Available online: https:\/\/www.un.org\/sustainabledevelopment\/inequality."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.3390\/curroncol29050303","article-title":"HPV vaccination: An underused strategy for the prevention of cancer","volume":"29","author":"Shapiro","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2471\/BLT.06.038414","article-title":"Human papillomavirus and HPV vaccines: A review","volume":"85","author":"Cutts","year":"2007","journal-title":"Bull. World Health Organ."},{"key":"ref_14","unstructured":"WHO (2022). WHO Updates Recommendations on HPV Vaccination Schedule, WHO."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103290","DOI":"10.1016\/j.eclinm.2025.103290","article-title":"Global HPV vaccination programs and coverage rates: A systematic review","volume":"84","author":"Han","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jadohealth.2025.08.002","article-title":"Adolescent and School-Based Vaccination: Crucial Components of Life Course Vaccination Globally","volume":"77","author":"Bloem","year":"2025","journal-title":"J. Adolesc. Health"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41256-024-00380-z","article-title":"Accelerating HPV vaccination in Africa for health equity","volume":"9","author":"Asempah","year":"2024","journal-title":"Glob. Health Res. Policy"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Roy, S., Wysong, M.D., Rosser, E.N., Sheth, I., Geddes, C., Limaye, R.J., and Rosen, J.G. (2025). Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: A qualitative study. PLoS Glob. Public Health, 5.","DOI":"10.1371\/journal.pgph.0004245"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ilic, I., and Ilic, M. (2025). Human Papillomavirus Vaccination Coverage Estimates Among the Primary Target Cohort (9\u201314-Year-Old Girls) in the World (2010\u20132024). Vaccines, 13.","DOI":"10.3390\/vaccines13101010"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"127015","DOI":"10.1016\/j.vaccine.2025.127015","article-title":"Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9\u201314 years: A randomized and open-label clinical trial","volume":"55","author":"Xie","year":"2025","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1473-3099(25)00031-3","article-title":"Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9\u201314 years in Ghana and Bangladesh: A randomised, controlled, open-label, non-inferiority, phase 3 trial","volume":"25","author":"Agbenyega","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1016\/j.vaccine.2021.04.025","article-title":"National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation","volume":"40","author":"Mphuru","year":"2022","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kolek, C.O., Opanga, S.A., Okalebo, F., Birichi, A., Kurdi, A., Godman, B., and Meyer, J.C. (2022). Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya-Findings and Implications. Vaccines, 10.","DOI":"10.3390\/vaccines10081185"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Osuagwu, U.L., Mashige, K.P., Ovenseri-Ogbomo, G., Envuladu, E.A., Abu, E.K., Miner, C.A., Timothy, C.G., Ekpenyong, B.N., Langsi, R., and Amiebenomo, O.M. (2023). The impact of information sources on COVID-19 vaccine hesitancy and resistance in sub-Saharan Africa. BMC Public Health, 23.","DOI":"10.1186\/s12889-022-14972-2"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"126425","DOI":"10.1016\/j.vaccine.2024.126425","article-title":"Enhancing HPV vaccine uptake in girls and boys\u2014A qualitative analysis of Canadian school-based vaccination programs","volume":"42","author":"Gagnon","year":"2024","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100685","DOI":"10.1016\/j.jvacx.2025.100685","article-title":"HPV vaccination campaigns in Ethiopia and Bangladesh: Strategic implementation, challenges, identifying best practices and lessons for success in low and middle-income countries","volume":"25","author":"Sayem","year":"2025","journal-title":"Vaccine X"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1112981","DOI":"10.3389\/fpubh.2023.1112981","article-title":"Planning, implementation, and sustaining high coverage of human papillomavirus (HPV) vaccination programs: What works in the context of low-resource countries?","volume":"11","author":"Waheed","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1667727","DOI":"10.3389\/fgwh.2025.1667727","article-title":"National human papillomavirus vaccination (GH_PV) programme: Ghana at a crossroads; is vaccine supply alone enough to ensure success?","volume":"6","author":"Nartey","year":"2025","journal-title":"Front. Glob Womens Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3332\/ecancer.2024.1735","article-title":"\u2018Addressing HPV vaccine hesitancy: Unveiling concerns and building trust\u2019 perspectives of adolescent girls and parents in Kisumu County, Kenya","volume":"18","author":"Ochomo","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Haddison, E.C., Engoung, D.B., Bodo, C.B., and Njie, V.M. (2025). Overcoming HPV vaccine hesitancy: Insights from a successful school-based vaccination campaign in the Saa health district of Cameroon. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-10864-z"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:57:24Z","timestamp":1781693844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060537"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060537","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]}}}